UroGen Pharma Ltd. Ordinary Shares (URGN) is a publicly traded Healthcare sector company. As of July 8, 2026, URGN trades at $37.59 with a market cap of $1.82B and a P/E ratio of -13.98. URGN moved -0.89% today. Year to date, URGN is +62.93%; over the trailing twelve months it is +179.84%. Its 52-week range spans $3.42 to $39.59. Analyst consensus is strong buy with an average price target of $36.63. Rallies surfaces URGN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
FDA Clears UroGen’s IND for UGN-501, Phase 1 Trial to Launch Q4 2026: The FDA has cleared UroGen’s IND application for UGN-501, enabling a Phase 1 intravesical study in non-muscle invasive bladder cancer patients slated for Q4 2026. UGN-501 is a next-generation oncolytic virus designed to destroy bladder tumor cells while inducing an anti-tumor immune response.
| Metric | Value |
|---|---|
| Price | $37.59 |
| Market Cap | $1.82B |
| P/E Ratio | -13.98 |
| EPS | $-2.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $39.59 |
| 52-Week Low | $3.42 |
| Volume | 142.18K |
| Avg Volume | 0 |
| Revenue (TTM) | $140.49M |
| Net Income | $-133.22M |
| Gross Margin | 89.85% |
8 analysts cover URGN: 0 strong buy, 7 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $36.63.